Analysts are intrested in these 5 stocks: ( (SLDB) ), ( (APPS) ), ( (RDW) ), ( (BAC) ) and ( (SMG) ). Here is a breakdown of their recent ratings and the rationale behind them.
Solid Biosciences is suddenly on the radar as UBS analyst Joon Lee initiates coverage on SLDB with a Buy rating and a $20 target, arguing the market is missing the commercial potential of its DMD gene therapy SGT-003. With functional data and an FDA meeting expected around late 2026 to early 2027, and a possible BLA filing by mid-2027, investors are being told this story is just getting started.
The analyst highlights more than 50 patients dosed with SGT-003 and a safety profile that avoids heavy immunosuppression, a key differentiator versus rival AAV therapies. Biomarkers linked to muscle damage have fallen meaningfully while indicators of new muscle formation also improved, supporting 2035 sales forecasts ahead of consensus and suggesting a large slice of an estimated $25B DMD market could be in play.
Beyond DMD, Solid is pushing SGT-212 for Friedreich ataxia, with first Phase 1b data expected in early 2027 and billions in long-term sales modeled versus more cautious street views. UBS applies a 2.5x EV to discounted 2035 sales, in line with peers, and notes a pipeline plus cash position that together justify the $20 price target. For biotech investors willing to wait for clinical and regulatory catalysts, SLDB is being framed as a mispriced rare-disease platform.
Digital Turbine’s rebound story is gaining momentum as analyst Richard Baldry resumes coverage of APPS with a Buy and a $19 target, leaning on sharply accelerating revenue growth through fiscal 2026 and into 2027. The company’s ability to push growth above 15% while expanding adjusted EBITDA is at the center of the bullish thesis, even after a share price run of more than 70% over the past year.
Baldry argues key growth drivers are durable, from strong global smartphone shipments to ad budgets shifting into mobile as AI-powered search reshapes the open web. APPS is also leaning into its own AI tools, using first-party device data from its Ignite Graph to sharpen ad targeting and attract more top-tier brands, a combination the analyst believes can sustain higher growth and margin leverage.
The report notes that management’s upgraded fiscal 2027 guidance still looks conservative, given current revenue and EBITDA run-rates and typical seasonal boosts in the middle quarters. With leverage already declining and a likely refinancing poised to cut interest costs by up to $15M a year, the balance sheet is expected to improve. Valuation is another hook for investors, as the stock trades at about 2.3x run-rate revenue versus roughly 3.1x for similar software peers, leaving room for multiple expansion.
Space-tech name Redwire is drawing a more cautious response, with Piper Sandler’s Clarke Jeffries initiating RDW at Neutral and an $11 price target. The company’s pitch is ambitious, spanning spacecraft, satellite components, and unmanned aerial systems, but the analyst questions whether Redwire has enough scale in either space or defense to deliver standout financial performance.
Redwire has evolved from a supplier of solar arrays, docking systems, and avionics into a budding prime contractor with its own satellite platforms like SabreSat and Phantom, aimed at multiple orbits including very low Earth orbit. The 2025 acquisition of Edge Autonomy added battle-tested drones and high-end gimbals, giving Redwire exposure to U.S. and NATO defense contracts and setting up a multi-domain intelligence platform.
The company is also targeting future niches like VLEO for sharper imaging and lower latency, as well as microgravity manufacturing for pharmaceuticals, areas that could support a forecast compound growth rate of roughly 24% through 2030. However, Jeffries underscores headwinds from intense competition, fragmented end markets, and a large European revenue mix, leaving investors with an intriguing but still unproven growth story that may need time to justify a higher rating.
Bank of America has shifted back into favor with Baird’s David George upgrading BAC to Outperform and setting a $62 price target, arguing that the latest sell-off after a softer third quarter looks overdone. While adjusted pre-provision earnings missed expectations on weak trading and investment banking, the analyst sees a stronger 2027 net interest income outlook and a path to the bank’s 200 to 300 basis point operating leverage goal.
Net interest income rose about 8% year over year on a better loan mix and improving net interest margin, while the bank’s huge deposit base continues to fund growth without aggressive rate chasing. Weak markets revenue and investment banking fees were partially offset by a healthy wealth management franchise and solid expense control, and credit trends remain benign with low charge-offs and a small reserve release, supporting the view that BAC’s risk profile is still manageable.
With the stock trading near 10x Baird’s 2027 EPS estimate of about $5.10, George calls that $5.00 per-share earnings a realistic floor even if markets stay choppy. Capital returns remain robust, with billions in buybacks and dividends, and core capital ratios are above minimums despite regulatory charges. For investors looking for a large, diversified U.S. bank with improving NII and reasonable valuation, BAC is being cast as a value opportunity rather than a value trap.
For more domestically focused investors, Scotts Miracle-Gro is getting a fresh endorsement as UBS analyst Peter Grom upgrades SMG to Buy with a revised $70 price target, seeing roughly 40% upside from current levels. After an upbeat analyst day in August, the shares have badly lagged, and the market appears skeptical that the lawn and garden specialist can deliver earnings growth through 2027.
Grom counters that view, noting historically resilient sales even amid higher rates and a soft housing backdrop, with the exception of the COVID boom and bust. Household penetration has held steady, and a growing share of revenue now comes from higher-income consumers, suggesting better insulation from downturns and giving confidence in low single-digit top line growth that edges ahead of consensus estimates over the next couple of years.
On profitability, Scotts has already lifted gross margins materially since 2022 and is expected to keep expanding margins despite inflation running toward the high end of management’s guidance. Pricing power from leading brands and early-stage productivity and mix initiatives are central to that call, supporting a longer-term margin framework. Valuation is anchored on a blend of price-to-earnings and EV/EBITDA multiples that remain compressed versus history, leaving what the analyst views as an attractive skew: significant upside if the company hits its algorithm and limited downside if growth stays merely modest.